Xenon Pharmaceuticals
XENE
63 hedge funds and large institutions have $180M invested in Xenon Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
64% more capital invested
Capital invested by funds: $110M → $180M (+$70.1M)
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
9% more funds holding
Funds holding: 58 → 63 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.26% less ownership
Funds ownership: 69.15% → 68.88% (-0.26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.66M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.06M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$1M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$921K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$838K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.58M |
| 2 |
Two Sigma Investments
New York
|
-$1.2M |
| 3 |
Millennium Management
New York
|
-$823K |
| 4 |
JP Morgan Chase
New York
|
-$792K |
| 5 |
Renaissance Technologies
New York
|
-$792K |
XENE Hedge Fund Activity: Q1 2019 in Review
63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2019, worth a combined $180M — up 64% from $110M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new XENE positions and 3 closed out — a net gain of 5 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $1.66M. The largest seller was Citadel Advisors, cutting an estimated $1.58M.
- 63 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2019, up from 58 in Q4 2018.
- Funds reported $180M of Xenon Pharmaceuticals stock for Q1 2019, up 64% quarter-over-quarter.
- 8 funds opened new Xenon Pharmaceuticals positions in Q1 2019 and 3 closed out, a net change of +5 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2019 was Eventide Asset Management, an estimated $1.66M added.
- The largest Xenon Pharmaceuticals seller in Q1 2019 was Citadel Advisors, an estimated $1.58M sold.
Based on aggregated 13F filings for Q1 2019.